Eli Lilly and Company (LLY)财务
NYSE · Healthcare · Drug Manufacturers - General · 员工50,000人 · CEO David A. Ricks
- 股价
- $1,417.54 +3.19%
- 市值
- $1.33万亿
- 企业价值
- $1.38万亿
- 最近财报
- Q3 '26 2026-10-29提交
- 下次财报
- 2027-02-03 EPS预期 $11.07
营收(TTM)$865亿+45.5% 对比去年同期最近4个季度;柱状图=各季度
营业利润率(TTM)46.1%+1.7 百分点 对比去年同期营业利润 $398亿
净利润(TTM)$276亿+49.8% 对比去年同期税后,含营业外收益
自由现金流(TTM)$197亿+118.0% 对比去年同期资本支出 $110亿
稀释EPS(TTM)$30.81+50.7% 对比去年同期最近4个季度之和
净现金-$446亿-36.9% 对比去年同期现金 + 短期投资 - 债务
估值与关键数据
- 市值
- $1.33万亿 EV $1.38万亿
- 营收
- $865亿 过去12个月
- 营收增速
- +39% FY2026年一致预期
- 净利润率
- 31.9% 净利润 / 营收,TTM
- P/E
- 45.9× 预期 40.3×(FY2026)
- P/S
- 15.4× 股价 / 营收,TTM
- EV / EBITDA
- 30.8× TTM
- 自由现金流
- $197亿 过去12个月
- 净利润
- $276亿 过去12个月
- 营收预期
- $904亿 FY2026年一致预期
- 盈利
- 2027-02-03 营收预期 $244亿
- 股息
- $6.69 每股,过去12个月
核心要点
根据披露数据计算,每条结论都附有其依据的数字。
- 最近财报(2026-10-29):营收超预期8.0%,EPS 超预期31.0%营收$244亿,预期$226亿(+8.0%);EPS $7.48,预期$5.71(+31.0%)。
- 营收增长放缓:同比38.6%Q3 '26营收$244亿,此前四个季度的平均值为49.9%。
- 营业利润率46.1%(TTM),较去年同期+1.7 百分点营收增长45.5%,营业利润增长50.9%。
- 税前利润的14.6%被营业外亏损吞噬税前利润$348亿,营业利润$398亿(TTM)。股权投资亏损等一次性项目压低了净利润和EPS,营业利润更能反映业务本身。
- 资本支出占营收的12.7%(去年为11.9%)最近4个季度投入$110亿(同比+56.0%)。自由现金流$197亿,相当于净利润的71.3%。
- 股东回报$118亿 = 自由现金流的60.1%回购$58.4亿(去年为$46.5亿),股息$59.8亿,股权激励$6.98亿(TTM)。
- 稀释股数一年内减少0.6%Q3 '26稀释股数8.93亿,一年前为8.99亿。
- 净债务 $446亿现金 + 短期投资 $48.9亿,含租赁债务 $495亿;一年前净债务 $326亿。
上一季度:Q3 '26
截至2026-09-30的季度。与去年同期及财报发布前的分析师一致预期对比。
本季度与去年同期
| Q3 '26 | 去年同期 | 变化 | |
|---|---|---|---|
| 营收 | $244亿 | $176亿 | +38.6% |
| 毛利率 | 83.9% | 82.9% | +1.0 百分点 |
| 营业利润 | $86.1亿 | $83.9亿 | +2.6% |
| 营业利润率 | 35.3% | 47.6% | -12.4 百分点 |
| 净利润 | $64.5亿 | $55.8亿 | +15.6% |
| 稀释EPS | $7.22 | $6.21 | +16.3% |
| 经营现金流 | $114亿 | $88.4亿 | +29.0% |
| 资本支出 | $31.8亿 | $2.24亿 | +1,319.4% |
| 自由现金流 | $82.2亿 | $86.1亿 | -4.6% |
| R&D | $42.5亿 | $34.7亿 | +22.5% |
| 股权激励费用 | $2亿 | $1.51亿 | +32.4% |
实际 vs 一致预期
2026-10-29| 实际 | 一致预期 | 对比预期 | |
|---|---|---|---|
| 营收 | $244亿 | $226亿 | +8.0% |
| EPS(一致预期口径) | $7.48 | $5.71 | +31.0% |
来自2026-10-29发布的Q3 '26财报：营收及分析师预期口径的EPS（通常为调整后），可能与上方报表中的EPS不同。
EPS与一致预期
最近8次财报营收
收入从何而来,按业务线和地区逐季展示。
营收、营业利润与增速
季度按业务线划分的营收
堆叠,季度| 分部 | Q3 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| Cardiometabolic Health | $198亿 | +50.0% | 81.5% | – | – | |
| Oncology | $26亿 | +8.0% | 10.7% | – | – | |
| Neuroscience | $4.44亿 | +40.6% | 1.8% | – | – | |
| Immunology | $14.4亿 | +5.3% | 5.9% | – | – | |
| Other Product, Total | – | – | – | – | – |
按地区划分的营收
占总额比例| 分部 | Q3 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| United States | $151亿 | +33.9% | 62.0% | $545亿 | +37.6% | |
| Non-US | $32.1亿 | +90.0% | 13.1% | $187亿 | +279.7% | |
| Europe | $44.6亿 | +27.5% | 18.3% | $153亿 | +40.4% | |
| CHINA | $9.47亿 | +69.0% | 3.9% | $30.5亿 | +60.3% | |
| JAPAN | $6.48亿 | +16.8% | 2.7% | $25亿 | +22.8% |
利润率与成本结构
每一单位营收在各层级还剩多少,成本又花在哪里。
利润率
季度成本占营收比例
季度现金流与资本配置
创造了多少现金,用在何处,又有多少回到股东手中。
经营现金流、资本支出、自由现金流
季度现金用途与经营现金流
财年最近4个季度
现金流量表- 经营现金流
- $306亿
- 资本支出
- -$110亿
- 股票回购
- -$58.4亿
- 股息
- -$59.8亿
- 收购
- -$108亿
- 债务净发行
- $73.2亿
- 股权激励费用
- $6.98亿
- 自由现金流
- $197亿
- 股东回报 / FCF
- 60.1%
股数与EPS
季度,稀释资产负债表
各季度末的流动性、投资和债务。
现金、投资与债务
季度末估值与回报
当前估值倍数与公司自身过去五个财年对比;分析师目标价与评级。
估值倍数与回报
TTM与过去5个财年| 当前 | 5年均值 | 当前处于5年区间的位置 | |
|---|---|---|---|
| P/E(TTM) | 45.9× | 63.0× | 46.6× – 100.0× |
| EV / EBITDA | 30.8× | 42.0× | 31.6× – 63.8× |
| EV / 营收 | 15.9× | 14.0× | 9.8× – 16.1× |
| 股价 / FCF | 67.8× | 104.2× 5年中的4年 | 48.9× – 184.9× |
| 股价 / 净资产 | 31.4× | 39.2× | 29.3× – 49.0× |
| FCF收益率 | 1.5% | 0.8% | -0.6% – 2.0% |
| 投入资本回报率 | 30.5% | 23.9% | 19.8% – 30.2% |
| 净资产收益率 | 83.6% | 64.4% | 48.6% – 77.8% |
分析师
一致目标价 $1,433.72 (+1.1%)
区间 $940.00 – $1,650.00 · 评级 Buy
强烈买入0
买入34
持有9
卖出3
强烈卖出0
展望
分析师对未来财年的一致预期,以及按当前股价意味着什么。
一致预期
| 财年 | 营收 | 增速 | EPS | 增速 | 按当前股价的P/E | 分析师(EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $904亿 | +38.7% | $35.15 | +53.2% | 40.3× | 12 |
| FY2027 | $1050亿 | +16.4% | $49.36 | +40.4% | 28.7× | 15 |
| FY2028 | $1180亿 | +11.8% | $56.62 | +14.7% | 25.0× | 9 |
| FY2029 | $1280亿 | +8.7% | $64.50 | +13.9% | 22.0× | 3 |
| FY2030 | $1380亿 | +8.2% | $71.19 | +10.4% | 19.9× | 3 |
财务报表
利润表、资产负债表和现金流量表的每一项,含12个季度和10个财年,以金额、占营收比例或增速展示。
全部披露项目
Eli Lilly and Company在近期10-Q / 10-K文件中标记的全部197项数据,附SEC官方标签和定义,包括附注(租赁、税务、回购、员工等)。
| 项目(SEC标签) | 最近季度 | 去年同期 | 同比 | 最近财年 | 上一财年 | 同比 |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $57.9亿 | $42.6亿 | +35.9% | $53.8亿 | $32.3亿 | +66.6% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $221亿 | $161亿 | +37.1% | $178亿 | $110亿 | +61.4% |
| Accounts Receivable, Allowance for Credit Loss, Current | $2170万2025-09-30 | $1570万 | +38.2% | $1490万2024-12-31 | $1480万 | +0.7% |
| Accrued Income Taxes, Noncurrent | $60.7亿 | $62.9亿 | -3.6% | $58.8亿 | $40.6亿 | +44.7% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $134亿 | $124亿 | +7.8% | $126亿 | $118亿 | +6.5% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$26.3亿 | -$32.1亿 | +18.0% | -$28.8亿 | -$43.2亿 | +33.4% |
| Additional Paid in Capital, Common Stock | $73.1亿 | $72.3亿 | +1.1% | $73.5亿 | $74.4亿 | -1.3% |
| Advertising Expense | – | – | – | $29亿 | $14亿 | +107.1% |
| Amortization of Intangible Assets | – | – | – | $4.88亿 | $5.53亿 | -11.8% |
| Assets | $1480亿 | $1150亿 | +28.8% | $1120亿 | $787亿 | +42.9% |
| Assets, Current | $653亿 | $621亿 | +5.1% | $556亿 | $327亿 | +69.9% |
| Cash and Cash Equivalents, at Carrying Value | $48.9亿 | $97.9亿 | -50.1% | $72.7亿 | $32.7亿 | +122.4% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | $48.9亿 | $97.9亿 | -50.1% | $72.7亿 | $32.7亿 | +122.4% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | -$40.7亿 | $64.2亿 | -163.4% | $40亿 | $4.49亿 | +790.9% |
| Commercial Paper | $02025-12-31 | $43.4亿 | -100.0% | $0 | $43.4亿 | -100.0% |
| Common Stock, Dividends, Per Share, Declared | $0.00 | $0.00 | – | $6.23 | $5.40 | +15.4% |
| Common Stock, Shares Authorized | 32亿2025-12-31 | 32亿 | 0.0% | 32亿 | 32亿 | 0.0% |
| Common Stock, Shares Held in Employee Trust | $30.1亿 | $30.1亿 | 0.0% | $30.1亿 | $30.1亿 | 0.0% |
| Common Stock, Shares Held in Employee Trust, Shares | 5000万2025-12-31 | 5000万 | 0.0% | 5000万 | 5000万 | 0.0% |
| Common Stock, Shares, Issued | 9.45亿2025-12-31 | 9.48亿 | -0.3% | 9.45亿 | 9.48亿 | -0.3% |
| Common Stock, Value, Issued | $5.88亿 | $5.91亿 | -0.6% | $5.9亿 | $5.92亿 | -0.3% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $65.8亿 | $60.9亿 | +8.0% | $221亿 | $106亿 | +108.4% |
| Cost of Goods and Services Sold | $39.3亿 | $30.1亿 | +30.8% | $111亿 | $84.2亿 | +31.3% |
| Current Federal Tax Expense (Benefit) | – | – | – | $46.4亿 | $33.4亿 | +38.8% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $21.6亿 | $14.3亿 | +51.0% |
| Current Income Tax Expense (Benefit) | – | – | – | $68亿 | $47.7亿 | +42.4% |
| Debt Securities, Available-for-sale | $3.56亿2025-09-30 | $6.85亿 | -48.0% | $6.69亿2024-12-31 | $6.57亿 | +1.8% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $330万2025-09-30 | $720万 | -54.2% | $160万2024-12-31 | $340万 | -52.9% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $1110万2025-09-30 | $2920万 | -62.0% | $4320万2024-12-31 | $3790万 | +14.0% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 | $1.6亿2025-09-30 | $2.93亿 | -45.4% | $2.55亿2024-12-31 | $2.47亿 | +3.2% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 | $6380万2025-09-30 | $1.01亿 | -36.7% | $9330万2024-12-31 | $9840万 | -5.2% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five | $1.19亿2025-09-30 | $1.85亿 | -35.5% | $2.26亿2024-12-31 | $2.28亿 | -1.1% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | $1270万2025-09-30 | $1.06亿 | -88.0% | $9520万2024-12-31 | $8410万 | +13.2% |
| Debt Securities, Available-for-sale, Unrealized Loss Position | $1.77亿2025-09-30 | $3.68亿 | -51.8% | $4.91亿2024-12-31 | $4.52亿 | +8.7% |
| Debt, Current | $25.2亿 | $16.3亿 | +54.1% | $16.4亿 | $51.2亿 | -68.0% |
| Debt, Long-term and Short-term, Combined Amount | $425亿2025-12-31 | $336亿 | +26.3% | $425亿 | $336亿 | +26.3% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | -$11.5亿 | -$22.1亿 | +48.0% |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | -$5.58亿 | -$4.73亿 | -18.0% |
| Deferred Income Tax Assets, Net | $110亿 | $89.6亿 | +22.2% | $99.6亿 | $80亿 | +24.5% |
| Deferred Income Tax Expense (Benefit) | – | – | – | -$17.1亿 | -$26.8亿 | +36.4% |
| Deferred Tax Assets, Goodwill and Intangible Assets | $17.2亿2025-12-31 | $17.8亿 | -3.4% | $17.2亿 | $17.8亿 | -3.4% |
| Deferred Tax Assets, Gross | $156亿2025-12-31 | $124亿 | +25.6% | $156亿 | $124亿 | +25.6% |
| Deferred Tax Assets, in Process Research and Development | $45.2亿2025-12-31 | $46亿 | -1.8% | $45.2亿 | $46亿 | -1.8% |
| Deferred Tax Assets, Inventory | $7.11亿2025-12-31 | $0 | – | $7.11亿 | $0 | – |
| Deferred Tax Assets, Net | $98.4亿2025-12-31 | $79.3亿 | +24.1% | $98.4亿 | $79.3亿 | +24.1% |
| Deferred Tax Assets, Net of Valuation Allowance | $144亿2025-12-31 | $115亿 | +25.5% | $144亿 | $115亿 | +25.5% |
| Deferred Tax Assets, Operating Loss Carryforwards | $9.11亿2025-12-31 | $5.87亿 | +55.2% | $9.11亿 | $5.87亿 | +55.2% |
| Deferred Tax Assets, Other | $10亿2025-12-31 | $5.99亿 | +67.6% | $10亿 | $5.99亿 | +67.6% |
| Deferred Tax Assets, Tax Credit Carryforwards | $6.49亿2025-12-31 | $5.77亿 | +12.5% | $6.49亿 | $5.77亿 | +12.5% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits | $5.56亿2025-12-31 | $5.65亿 | -1.6% | $5.56亿 | $5.65亿 | -1.6% |
| Deferred Tax Assets, Valuation Allowance | $12.2亿2025-12-31 | $9.64亿 | +26.9% | $12.2亿 | $9.64亿 | +26.9% |
| Deferred Tax Liabilities, Goodwill and Intangible Assets | $12.6亿2025-12-31 | $11.8亿 | +7.0% | $12.6亿 | $11.8亿 | +7.0% |
| Deferred Tax Liabilities, Gross | $45.4亿2025-12-31 | $35.3亿 | +28.7% | $45.4亿 | $35.3亿 | +28.7% |
| Deferred Tax Liabilities, Other | $3.81亿2025-12-31 | $4.14亿 | -8.0% | $3.81亿 | $4.14亿 | -8.0% |
| Deferred Tax Liabilities, Prepaid Expenses | $7.07亿2025-12-31 | $6.11亿 | +15.7% | $7.07亿 | $6.11亿 | +15.7% |
| Deferred Tax Liabilities, Property, Plant and Equipment | $9.07亿2025-12-31 | $5.58亿 | +62.5% | $9.07亿 | $5.58亿 | +62.5% |
| Deferred Tax Liabilities, Undistributed Foreign Earnings | $12.9亿2025-12-31 | $7.73亿 | +67.0% | $12.9亿 | $7.73亿 | +67.0% |
| Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease) | – | – | – | $8.98亿 | -$9.3亿 | +196.6% |
| Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation | $23.6亿2025-12-31 | $23亿 | +2.7% | $23.6亿 | $23亿 | +2.7% |
| Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets | $10.6亿2025-12-31 | $10.6亿 | +0.3% | $10.6亿 | $10.6亿 | +0.3% |
来源:SEC companyfacts(每份10-Q / 10-K的XBRL)。现金流量表的季度数据由10-Q标记的年初至今累计数推算。分部拆分带有维度标记,在分部章节中单独展示。
数据来源
报表、分部营收、指标、预期:Financial Modeling Prep。分部利润及全部披露项目:SEC EDGAR(XBRL)。 已读取的文件: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
数据截至 2026-11-01